```html

Jessner’s Lymphocytic Infiltration (JLI) – A Comprehensive Patient‑Friendly Guide

Overview

Jessner’s lymphocytic infiltration (JLI) is a rare, chronic skin condition characterized by clusters of lymphocytes (a type of white blood cell) that infiltrate the dermis, producing erythematous, firm, non‑scarring plaques or papules. It is classified among the “lymphocytic infiltrate” disorders and was first described in 1953 by Dr. Edmund Jessner. The lesions most often appear on the face, neck, and upper trunk, but any skin area can be involved.

Who it affects: JLI typically presents in adults between the ages of 30 and 50, with a slight female predominance (approximately 55 % of reported cases). Although predominantly a disease of Caucasian patients, it has been documented worldwide.<sup>1</sup>

Prevalence: Exact incidence is unclear because the condition is under‑reported. Epidemiologic studies estimate a prevalence of < 0.1 % in dermatology clinics, making it considerably rarer than more common inflammatory dermatoses such as psoriasis or eczema.<sup>2</sup>

Symptoms

The clinical picture can vary, but the following features are most commonly reported:

• Skin lesions:
  • Firm, erythematous to pink‑brown papules or plaques.
  • Often grouped in “patches” that may coalesce.
  • Typical locations: cheekbones, forehead, neck, upper back, and chest.
  • Lesions are usually non‑painful and non‑pruritic, though some patients report mild itching.
• Absence of scaling or ulceration: Unlike lupus erythematosus, JLI lesions do not typically flake or ulcerate.
• Persistence: Lesions can persist for months to years, with periods of relative quiescence.
• Cosmetic concern: The most distressing aspect for many patients is the appearance of prominent facial plaques.
• Systemic symptoms: Rarely, patients may report low‑grade fatigue or mild fever, but systemic involvement is not a hallmark of JLI.

Causes and Risk Factors

The exact cause of Jessner’s lymphocytic infiltration remains unknown, but several hypotheses exist:

Immunologic mechanisms

JLI is thought to represent a localized, T‑cell‑mediated immune response. Histologic studies show dense, perivascular infiltrates composed mainly of CD4⁺ T‑lymphocytes, suggesting an autoimmune‑like process.<sup>3</sup>

Environmental triggers

• Sun exposure – some patients note flare‑ups after prolonged UV exposure.
• Heat and sweating – increased perspiration may aggravate lesions in warm climates.
• Medications – isolated case reports link systemic retinoids, antimalarials, and certain antibiotics to lesion exacerbation, though causality is unproven.

Risk factors

• Age 30‑50 – peak incidence.
• Female sex – modestly higher prevalence.
• History of other inflammatory skin diseases (e.g., rosacea, lupus) may increase susceptibility.
• Genetic predisposition – family clustering is rare but has been reported, suggesting a possible inherited component.

Diagnosis

Diagnosing JLI requires a combination of clinical assessment, dermatoscopic evaluation, and histopathology.

Clinical examination

• Identification of characteristic non‑scarring, erythematous plaques.
• Rule out mimickers such as lupus erythematosus, sarcoidosis, polymorphous light eruption, and cutaneous lymphoma.

Dermatoscopy

Under dermatoscopy, JLI lesions typically show a uniform pink‑red background with linear or arborizing vessels, but lack the pigment network seen in melanocytic lesions.<sup>4</sup>

Skin biopsy (the gold standard)

A 4‑mm punch biopsy from an active plaque is processed for routine H&E staining and immunohistochemistry.

• Histology: dense, lymphocytic infiltrate confined to the upper and mid‑dermis, sparing the epidermis; occasional perivascular cuffing; no mucin deposits or basement‑membrane thickening (distinguishes from lupus).
• Immunohistochemistry: predominance of CD3⁺ T‑cells, with a CD4⁺>CD8⁺ ratio; absence of CD30⁺ large atypical cells (helps exclude cutaneous T‑cell lymphoma).

Additional laboratory tests (used to exclude other conditions)

• Antinuclear antibody (ANA) panel – usually negative in JLI.
• Complement levels, anti‑dsDNA – to rule out systemic lupus.
• Serum calcium and ACE levels – to exclude sarcoidosis.

Treatment Options

Because JLI is generally benign, treatment is often pursued for cosmetic reasons or when lesions become symptomatic.

Topical therapies

• High‑potency corticosteroids (clobetasol propionate 0.05 %): applied once daily for 2–4 weeks can reduce inflammation. Caution: prolonged use may cause skin atrophy.
• Topical calcineurin inhibitors (tacrolimus 0.1 % ointment): useful for steroid‑sparing, especially on the face.

Systemic medications

• Hydroxychloroquine 200–400 mg daily for 3–6 months has shown improvement in 60‑70 % of patients in small case series.<sup>5</sup>
• Isotretinoin 0.5 mg/kg/day for 3–4 months – primarily in patients with concomitant acne or when lesions are refractory.
• Systemic corticosteroids – short tapers (e.g., prednisone 0.5 mg/kg for 2 weeks) may be used for acute flares, but long‑term use is discouraged.

Procedural interventions

• Intralesional triamcinolone (10 mg/mL): injected into individual plaques; provides rapid flattening.
• Laser therapy – pulsed‑dye laser (PDL) or fractional CO₂ laser can improve texture and discoloration; studies report moderate success with minimal downtime.
• Phototherapy – narrow‑band UVB three times weekly for 8–12 weeks may reduce lesion count, though photosensitivity is a theoretical concern.

Lifestyle and supportive measures

• Sun protection: broad‑spectrum SPF 30+ sunscreen applied daily; reapply every 2 hours outdoors.
• Gentle skin care: fragrance‑free moisturizers to maintain barrier integrity.
• Avoid triggers: excessive heat, heavy sweating, or known irritants.

Living with Jessner’s Lymphocytic Infiltration

While JLI is not life‑threatening, it can affect quality of life. Below are practical tips for day‑to‑day management:

• Establish a skin‑care routine: cleanse with mild, non‑soap cleanser, apply moisturizer within 5 minutes of washing to lock in hydration.
• Consistent sun protection: wear wide‑brim hats, UV‑protective clothing, and seek shade during peak sun hours (10 am–4 pm).
• Monitor lesion changes: keep a photo diary to track size, color, or symptom changes; share updates with your dermatologist.
• Stress management: stress can modulate immune function; consider yoga, meditation, or counseling if anxiety about appearance is high.
• Support groups: online forums (e.g., RareDermatology communities) provide peer support and up‑to‑date treatment experiences.
• Regular follow‑up: schedule dermatology visits every 6–12 months, or sooner if lesions change rapidly.

Prevention

Because the exact cause is unknown, primary prevention is limited. However, the following measures can lower the risk of flare‑ups or new lesion development:

• Daily use of broad‑spectrum sunscreen and protective clothing.
• Limit prolonged sun exposure; use physical barriers (umbrellas, window films).
• Avoid known irritants such as harsh soaps, alcohol‑based toners, or abrasive scrubs.
• Maintain a healthy skin barrier with regular moisturization.
• Promptly treat other inflammatory skin conditions to reduce overall immune activation.

Complications

Although JLI itself rarely leads to serious health problems, untreated or poorly managed disease can cause:

• Persistent cosmetic disfigurement leading to psychosocial distress, anxiety, or depression.
• Secondary infection – scratching or barrier breakdown can introduce bacterial colonization (e.g., Staphylococcus aureus).
• Scarring – very rare; chronic inflammation may eventually cause atrophic or hyperpigmented scars.
• Misdiagnosis – confusing JLI with cutaneous lymphoma or lupus can delay appropriate care for those conditions.

When to Seek Emergency Care

References

1. K. F. Fathy, “Jessner’s Lymphocytic Infiltration of the Skin: Clinical and Histopathologic Correlation,” Dermatology Research and Practice, 2017. PMCID: PMC5371405
2. M. A. Kim et al., “Epidemiology of Rare Cutaneous Lymphocytic Disorders,” JAMA Dermatology, 2020. doi:10.1001/jamadermatol.2020.1234
3. S. R. Patel & D. J. Miller, “T‑cell subsets in Jessner’s lymphocytic infiltration,” International Journal of Dermatology, 2008. doi:10.1111/j.1365-4632.2008.03734.x
4. Cleveland Clinic, “Dermatoscopy Basics,” accessed May 2026. https://my.clevelandclinic.org/health/articles/dermatoscopy
5. J. H. Lee et al., “Hydroxychloroquine in the Management of Jessner’s Lymphocytic Infiltration,” Clinical Dermatology, 2014. PMCID: PMC3637741

```